UBS Group’s NovoCure NVCR Stock Holding History

UBS Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-200	Closed	-$5.96K	–	10567
2024 Q4	$5.96K	Hold	200	–	–	﹤0.01%	8605
2024 Q3	$3.13K	Hold	200	–	–	﹤0.01%	8309
2024 Q2	$3.43K	Sell	200 -10,800	-98%	-$190K	﹤0.01%	8214
2024 Q1	$172K	Sell	11,000 -132,900	-92%	-$1.95M	﹤0.01%	5953
2023 Q4	$2.15M	Hold	143,900	–	–	﹤0.01%	3742
2023 Q3	$2.32M	Buy	143,900 +57,700	+67%	+$1.66M	﹤0.01%	3295
2023 Q2	$3.58M	Buy	86,200 +76,600	+798%	+$4.76M	﹤0.01%	2913
2023 Q1	$577K	Buy	9,600 +400	+4%	+$32K	﹤0.01%	4578
2022 Q4	$675K	Hold	9,200	–	–	﹤0.01%	4431
2022 Q3	$699K	Hold	9,200	–	–	﹤0.01%	4051
2022 Q2	$639K	Hold	9,200	–	–	﹤0.01%	4072
2022 Q1	$762K	Hold	9,200	–	–	﹤0.01%	4354
2021 Q4	$691K	Hold	9,200	–	–	﹤0.01%	4715
2021 Q3	$1.07M	Sell	9,200 -40,800	-82%	-$6.17M	﹤0.01%	4146
2021 Q2	$11.1M	Buy	+50,000	New	+$9.73M	﹤0.01%	1944
2021 Q1	–	Sell	-16,600	Closed	-$2.87M	–	9324
2020 Q4	$2.87M	Buy	16,600 +2,600	+19%	+$356K	﹤0.01%	3024
2020 Q3	$1.56M	Hold	14,000	–	–	﹤0.01%	3293
2020 Q2	$830K	Hold	14,000	–	–	﹤0.01%	3668
2020 Q1	$943K	Sell	14,000 -12,100	-46%	-$956K	﹤0.01%	3401
2019 Q4	$2.2M	Buy	26,100 +14,000	+116%	+$1.13M	﹤0.01%	3460
2019 Q3	$905K	Buy	+12,100	New	+$968K	﹤0.01%	4050

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

UBS Group's NVCR Position: Q2 2026 in Review

UBS Group increased its NovoCure (NVCR) stake by 19% in Q2 2026, buying an estimated $708K and bringing the position to 292,638 shares worth $4.43M. The position accounts for ﹤0.01% of the portfolio, ranked #4299.

UBS Group first reported a position in NVCR in Q4 2015 and has held it in 43 quarters since. The position peaked at $15.6M in Q4 2024. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

UBS Group held 292,638 shares of NovoCure worth $4.43M as of Q2 2026.
UBS Group bought 46,821 NovoCure shares in Q2 2026, an estimated $708K.
NovoCure made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4299 holding.
UBS Group first reported a position in NovoCure in Q4 2015 and has held it in 43 quarters since.
UBS Group's NovoCure position peaked at $15.6M in Q4 2024.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.